Why the study?
Optimal use of pulsed field ablation requires operators to adapt their procedural approach to the novel catheter and energy source, and standardized practices may reduce procedural heterogeneity.
This practical guide provides standardized procedural workflows for the PulseSelect pulsed field ablation system to optimize safety and efficacy in atrial fibrillation ablation.
Supports PulseSelect PFA integration into AF ablation practice; extends evidence for pulsed field ablation in paroxysmal and persistent AF.
Pulsed field ablation (PFA), which employs intermittent short-duration high-voltage electrical impulses to induce cellular membrane pore formation, is one of the most substantial innovations in the field of cardiac electrophysiology. In contrast to thermal ablation using radiofrequency or cryoenergy, PFA is theoretically capable of preferential tissue destruction, avoiding the negative effects of thermal energy and minimizing the risk of collateral damage. The optimal use of PFA requires operators to adapt their procedural approach to the novel catheter and energy source. The purpose of this manuscript is to summarize the best practice procedural considerations related to PFA with the PulseSelect ablation catheter, within the context of the contemporary evidence-base and with a focus on a predominantly fluoroscopy-based workflow. A foundational approach to pulmonary vein isolation with the PulseSelect catheter would reduce procedural heterogeneity, ultimately improving patient outcomes through the adoption of standardized evidence-based practices.
No takes yet. Share an insight, caveat, or question.
Andrade et al. (2026) conducted a review in Paroxysmal and persistent atrial fibrillation (n=300). PulseSelect PFA system was evaluated on Freedom from a composite end point of acute procedural failure, arrhythmia recurrence, or antiarrhythmic escalation through 12 months (66.2% in paroxysmal AF and 55.1% in persistent AF, 95% CI 57.9-73.2). The PulseSelect PFA system achieved freedom from the primary composite endpoint at 12 months in 66.2% of patients with paroxysmal AF and 55.1% of patients with persistent AF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: